AN2 Therapeutics, Inc. Common Stock
ANTXStock
$4.67+344.86%52W
Market Cap$168.20M
P/E—
Div yield—
Beta-1.00
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)336.18%
Price vs S&P 500 (4W)-2.66%
VGM Score94.17
Market Capitalization$168.20M
Earnings Surprise History
Q1 26-0.29est. -0.23
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.17
2.17
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANTXAN2 Therapeutics, Inc. Common Stock | — | — | A | $4.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
AN2 Therapeutics develops small molecule therapeutics using proprietary boron chemistry, targeting infectious diseases and oncology with significant unmet medical needs. Its pipeline includes programs for Chagas disease, non-tuberculous mycobacterial infections, and melioidosis, with additional early-stage oncology initiatives.